68Ga-NOTA-MAL-MZHER2 PET显像在晚期胃癌患者中的影响及治疗反应监测
研究纳入34例晚期胃癌患者(23例HER2阳性、11例HER2阴性),注射约3.7 MBq/kg 68Ga-HER2 affibody后行PET/CT,评估安全性、组织剂量学、HER2阳性病灶检测能力及靶向治疗监测效用。结果显示该affibody安全有效,最佳图像对比见于注射后2小时,平均有效吸收剂量0.0215 mSv/MBq,HER2阳性组摄取显著高于阴性组(SUVmax 10.7±12.5 vs 3.8±1.7,p=0.005),cutoff值6.6时特异度100%、敏感度55.4%。
要点
- 68Ga-HER2 affibody安全有效,最佳显像时间为注射后2小时,平均有效吸收剂量0.0215 mSv/MBq。
- HER2阳性组SUVmax 10.7±12.5显著高于HER2阴性组3.8±1.7(p=0.005),cutoff 6.6时特异度100%、敏感度55.4%。
- 骨转移摄取最高(SUVmax 40.5±24.9),肝转移11.9±3.9,淋巴结转移5.6±3.7,原发灶等其他病灶7.3±3.7。
核心结论
- 68Ga-HER2 affibody PET/CT是無创检测晚期胃癌患者HER2状态的可行方法,可实现低剂量早期检测。
- 正在进行的抗HER2治疗不影响68Ga-HER2 affibody显像,允许重复评估以监测抗HER2治疗后的HER2状态。
- 该方法提供晚期胃癌生物学的体内理解,最终帮助肿瘤科医生改进个体化治疗方案。
研究设计与样本
- 纳入34例晚期胃癌患者(23例HER2阳性、11例HER2阴性原发灶),注射约3.7 MBq/kg体重68Ga-HER2 affibody后行PET/CT。
- 13例患者(8例HER2阳性、5例HER2阴性)于注射后1、2、3小时扫描以确定最佳显像时间点,其余患者在优化时间点扫描。
- 所有患者7天内行标准18F-FDG PET/CT以识别可存活病灶,分析大于1.0 cm病灶的SUVmax,每个器官分析5个病灶最大值。
主要发现
- 68Ga-HER2 affibody安全有效,最佳图像对比见于注射后2小时,平均有效吸收剂量0.0215 mSv/MBq。
- HER2阳性组68Ga-HER2 affibody摄取显著高于HER2阴性组(SUVmax 10.7±12.5 vs 3.8±1.7,p=0.005)。
- 以SUVmax cutoff值6.6判断,特异度100%、敏感度55.4%;病灶SUVmax范围1.6至73.0,提示HER2表达异质性。
- HER2阳性患者中摄取呈器官依赖性差异:骨转移最高(SUVmax 40.5±24.9),其次肝转移(11.9±3.9)、淋巴结转移(5.6±3.7),原发灶等其他病灶相对较低(7.3±3.7)。
- 接受治疗患者病灶SUVmax非显著低于未接受治疗患者(8.8±4.9 vs 11.8±15.2,p=0.253);68Ga-HER2 affibody在1/11例HER2阴性原发胃癌患者中检出阳性病灶,经二代基因测序确认。
关键数值与推荐
- 注射剂量约3.7 MBq/kg体重,最佳显像时间点为注射后2小时,平均有效吸收剂量0.0215 mSv/MBq。
- HER2阳性判断SUVmax cutoff值6.6,特异度100%、敏感度55.4%。
- 10例患者基线PET/CT后接受靶向抗HER2治疗,病灶对68Ga-HER2 affibody高亲和者进展无生存期长于低亲和者(4-9个月 vs 2-3个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical PET imaging of human epidermal growth factor receptor 2 (HER2) can noninvasively detect HER2 overexpression in lesions. A novel 68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody was developed for clinical PET/CT, and its safety, tissue dosimetry, ability to detect HER2-positive lesions, and utility for HER2-targeted therapy in patients with advanced gastric cancer (AGC) were evaluated. METHODS: Thirty-four patients with AGC (23 with HER2-positive and 11 with HER2-negative primary lesions) were included and underwent PET/CT after an injection of approximately 3.7 MBq/kg body weight 68Ga-HER2 affibody. Thirteen patients (8 HER2-positive and 5 HER2-negative patients) were scanned at 1, 2, and 3 h post-injection to determine the best imaging timepoint, and the remaining patients were scanned at the optimized timepoint. All patients underwent standard 18F-FDG PET/CT within 7 d to identify viable lesions. The SUVmax of lesions larger than 1.0 cm were analyzed. Five lesion maxima were analyzed for each organ. RESULTS: (1) The 68Ga-HER2 affibody was safe and effective, and optimal image contrast was observed 2 h post-injection; the average effective absorbed dose was 0.0215 mSv/MBq. (2) The HER2-positive group had significantly higher 68Ga-HER2 affibody uptake than the HER2-negative group (SUVmax 10.7 ± 12.5 vs 3.8 ± 1.7, p = 0.005). The specificity and sensitivity were 100 and 55.4%, respectively, with a SUVmax cutoff value of 6.6. The SUVmax of the lesions ranged from 1.6 to 73.0, suggesting heterogeneity in HER2 expression. (3) 68Ga-HER2 affibody uptake showed an organ-dependent difference in patients with HER2-positive expression. Bone metastases had the highest uptake (SUVmax 40.5 ± 24.9), followed by liver metastases (SUVmax 11.9 ± 3.9) and lymph node metastases (SUVmax 5.6 ± 3.7), while the uptake in other lesions, including in the primary lesion, was relatively lower (SUVmax 7.3 ± 3.7). (4) Patients receiving therapy had a non-significantly lower lesion SUVmax than patients not receiving therapy (SUVmax 8.8 ± 4.9 vs 11.8 ± 15.2) (p = 0.253). Additionally, the 68Ga-HER2 affibody detected positive lesions in 1/11 patients with HER2-negative primary gastric cancer, which was confirmed by second generation gene sequencing. (5) Moreover, ten patients underwent baseline PET/CT followed by targeted anti-HER2 therapy. Patients with lesions showing high avidity to the 68Ga-HER2 affibody showed longer progression-free survival (PFS) than those with lesions showing low avidity (4-9 m vs 2-3 m). CONCLUSION: 68Ga-HER2 affibody PET/CT is a feasible method to noninvasively detect the HER2 status in AGC patients and enable early detection with a low dose. Ongoing anti-HER2 therapy did not influence 68Ga-HER2 affibody imaging, which allowed repeated evaluations to monitor the HER2 status after anti-HER2 therapy. This method provides an in vivo understanding of AGC biology that will ultimately help oncologists improve individualized therapy plans.
引用
- Zhou N, Liu C, Guo X, et al. Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. Eur J Nucl Med Mol Imaging. 2020. PMID: 32564171. doi:10.1007/s00259-020-04898-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。